LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR (Nasdaq: LNSR) has granted stock options to three newly-hired non-executive employees as inducement awards. The options, totaling 1,925 shares of common stock, were approved by a majority of independent board members and issued on August 1, 2024. With an exercise price of $5.20 per share, matching the closing price on the grant date, these options have a 10-year term and a vesting schedule of 25% after one year, followed by 36 monthly installments. The grants, made under LENSAR's 2024 Employment Inducement Incentive Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and aim to attract new talent to the company.
LENSAR (Nasdaq: LNSR) ha concesso opzioni su azioni a tre nuovi dipendenti non esecutivi come premi d'induzione. Le opzioni, per un totale di 1.925 azioni ordinarie, sono state approvate da una maggioranza dei membri indipendenti del consiglio e emesse il 1 agosto 2024. Con un prezzo di esercizio di 5,20 dollari per azione, che corrisponde al prezzo di chiusura alla data di concessione, queste opzioni hanno un termine di 10 anni e un piano di maturazione del 25% dopo un anno, seguito da 36 rate mensili. Le concessioni, effettuate nell'ambito del Piano di Incentivi per l'Occupazione 2024 di LENSAR, sono in conformità con la Regola 5635(c)(4) della Nasdaq e mirano ad attrarre nuovi talenti in azienda.
LENSAR (Nasdaq: LNSR) ha otorgado opciones sobre acciones a tres nuevos empleados no ejecutivos como premios de inducción. Las opciones, que suman un total de 1,925 acciones ordinarias, fueron aprobadas por la mayoría de los miembros independientes de la junta y emitidas el 1 de agosto de 2024. Con un precio de ejercicio de 5.20 dólares por acción, que coincide con el precio de cierre en la fecha de concesión, estas opciones tienen un plazo de 10 años y un calendario de adquisición del 25% después de un año, seguido de 36 instancias mensuales. Las concesiones, realizadas bajo el Plan de Incentivos para la Ocupación 2024 de LENSAR, cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq y tienen como objetivo atraer nuevo talento a la empresa.
LENSAR(Nasdaq: LNSR)는 세 명의 신입 비임원 직원에게 유인 상여로 주식 옵션을 부여했습니다. 총 1,925주에 해당하는 이 옵션은 독립 이사들의 대다수 승인을 받아 2024년 8월 1일에 발행되었습니다. 주당 5.20달러의 행사 가격으로, 부여일의 종가와 일치하며, 이 옵션은 10년의 기간을 가지며 1년 후 25%가 확정되고 이후 36개월의 월 할부로 진행됩니다. 이 부여는 LENSAR의 2024 고용 유인 인센티브 상여 제도에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)를 준수하며 회사에 새로운 인재를 유치하기 위해 목표하고 있습니다.
LENSAR (Nasdaq: LNSR) a accordé des options sur actions à trois nouveaux employés non dirigeants en tant que primes d'incitation. Les options, totalisant 1 925 actions ordinaires, ont été approuvées par la majorité des membres indépendants du conseil et émises le 1er août 2024. Avec un prix d'exercice de 5,20 $ par action, correspondant au prix de clôture à la date de concession, ces options ont un terme de 10 ans et un calendrier d'acquisition de 25 % après un an, suivi de 36 mensualités. Ces concessions, faites dans le cadre du Plan d'Incentive à l'Emploi 2024 de LENSAR, sont conformes à la règle d'inscription 5635(c)(4) de Nasdaq et visent à attirer de nouveaux talents dans l'entreprise.
LENSAR (Nasdaq: LNSR) hat drei neu eingestellte nicht-executive Mitarbeiter Aktienoptionsrechte als Anreizvergütung gewährt. Die Optionen, insgesamt 1.925 Stammaktien, wurden von der Mehrheit der unabhängigen Vorstandsmitglieder genehmigt und am 1. August 2024 ausgegeben. Mit einem Ausübungspreis von 5,20 $ pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht, haben diese Optionen eine Laufzeit von 10 Jahren und einen Vesting-Plan von 25 % nach einem Jahr, gefolgt von 36 monatlichen Raten. Die Gutscheine erfolgten im Rahmen des Beschäftigungsanreiz-Plan 2024 von LENSAR und entsprechen der Nasdaq-Listing-Regel 5635(c)(4), der darauf abzielt, neue Talente für das Unternehmen zu gewinnen.
- Attracting new talent with stock options as employment incentives
- Compliance with Nasdaq listing rules for inducement grants
- Potential dilution of existing shareholders' equity
The options have an exercise price of
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY® Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801634347/en/
Thomas R. Staab, II, CFO
ir.contact@lensar.com
Lee Roth / Cameron Radinovic
Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Source: LENSAR, Inc.
FAQ
How many shares of LENSAR (LNSR) stock were granted as options on August 1, 2024?
What is the exercise price of the LENSAR (LNSR) stock options granted on August 1, 2024?
What is the vesting schedule for the LENSAR (LNSR) stock options granted as inducement awards?
Under which plan were the LENSAR (LNSR) inducement stock options granted?
